REDWOOD CITY, Calif., May 12, 2014 /CNW/ - Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Lisa M. Bell, Ph.D. as Senior Vice President, Global Regulatory Affairs. Dr. Bell joins Coherus with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at preeminent biotech companies.
"Lisa brings a strong strategic, scientific and global mindset to the regulatory strategy for our programs," said Denny Lanfear, President and CEO of Coherus. "We are thrilled to have her join Coherus. Lisa's experience in overseeing global applications to approval and implementing cutting-edge regulatory strategies will be critical as we strive to obtain approved labels for ourselves and our partners."
"I am extremely pleased to join the extraordinary team at Coherus and share their commitment to deliver high-quality biosimilar therapeutics that will expand patient access to life-changing medicines worldwide." said Dr. Bell.
Dr. Bell most recently served as global head of Regulatory, Pharmacovigilance, Medical Writing and Development Quality Assurance at BioMarin Pharmaceutical. Previously she also held leadership roles at Facet Biotech and Genentech, Inc. Dr. Bell has extensive experience in driving regulatory strategy of large and small molecule programs from pre-clinical through post-marketing phases of development. She has worked across several therapeutic areas including oncology, neurology/inflammation and rare diseases. Dr. Bell earned her Bachelors (Biology) and Masters (Biotechnology) degrees from Boston University and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
About Coherus Biosciences
Coherus Biosciences is a leading biologics platform company focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medications worldwide. Headquartered in the San Francisco Bay Area and founded by a group of biotech pioneers who helped build America's first generation biotherapeutics industry, Coherus has developed a unique, collaborative business model that leverages a strategic consortium of key service providers aligned through ownership and shared incentives. Coherus' global commercialization partnerships include top tier biopharma companies in Europe, Asia, and Latin America.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.
Contact – Beth Jimison – email@example.com 650.649.3526
Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO
SOURCE: Coherus Biosciences, Inc.
For further information: